BIRC5 and pancreatic ductal adenocarcinoma: Ren et al. [52] analyzed the serum levels of survivin in patients with pancreatic ductal adenocarcinoma (PDAC) (n = 80) and age-matched healthy volunteers (n = 80) and found that the serum survivin concentrations were significantly elevated in the sera of PDAC patients compared with healthy sera (p = 0).